Therefore, approaches that upregulate and/or maintain SIRT3 expression and activity may represent a promising therapeutic strategy to treat or prevent cardiac dysfunction in the setting of MI [41,43,44]. The gene discussed is SIRT3; the disease is myocardial infarction.